Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, and other shareholders for $95 million.
Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, and other shareholders for $95 million.